Records treatment results and patient-reported outcomes in prostate cancer patients
Studies a digital system that records symptoms and results for adults with localized prostate cancer.
Plain-language title generated from the registry record
Registry title: Prospective Prostate Cancer and Patient-reported Outcomes Registry
Key facts
- Where
- Bruges, Dendermonde, Kortrijk, and Leuven, BelgiumSee the 4 sites
Where in Belgium
- Az Sint Jan BruggeBruges, BelgiumTaking people
- AZ Sint-BlasiusDendermonde, BelgiumTaking people
- AZ Groeninge, KortrijkKortrijk, BelgiumTaking people
- University Hospitals LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitaire Ziekenhuizen KU Leuven
- Trial code
- NCT04694924
- Record updated
- 22 May 2024
- Original description
This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.Read full original descriptionShow less
Promoting Quality of Care: a Prospective Cohort Study of Localized and Locally Advanced Prostate Cancer Patients
This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.
Inclusion: Pathology confirmed diagnosis of localized or locally advanced prostate cancer; Being able to speak, read and understand Dutch, French, or English; Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he understands the purpose of, and is willing to participate in the study.
Exclusion: Patients with prior treatment for prostate malignancies will be excluded; Dementia, mental alteration, or psychiatric pathology that can compromise informed consent from the patient and/ or adherence to the protocol and the monitoring of the trial; Patients who cannot submit themselves to following the protocol for psychological reasons, social, family, or geographical; Persons deprived of liberty or under guardianship.